Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;10(1):56-63.

Myostatin (GDF-8) as a key factor linking muscle mass and bone structure

Affiliations
Review

Myostatin (GDF-8) as a key factor linking muscle mass and bone structure

M N Elkasrawy et al. J Musculoskelet Neuronal Interact. 2010 Mar.

Abstract

Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-beta) superfamily that is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Summary of bony phenotypic changes associated with loss of myostatin function in mice. BMD: bone mineral density, BMC: bone mineral content, TMJ: temporomandibular joint, *: exercised knockout versus normal mice.
Fig. 2
Fig. 2
Radiographs demonstrating increased shaft diameter and increased muscle attachment site at the deltoid crest in humerus (a), and the third trochanter in femur (b) in Myostatin−/− mice compared to wild type. Notice the extension of the articular surface towards the neck of the femur (b).
Fig. 2
Fig. 2
Radiographs demonstrating increased shaft diameter and increased muscle attachment site at the deltoid crest in humerus (a), and the third trochanter in femur (b) in Myostatin−/− mice compared to wild type. Notice the extension of the articular surface towards the neck of the femur (b).
Fig. 3
Fig. 3
Spines from normal (WT) and myostatin-deficient mice (KO) cleared and stained in alizarin red showing the large spinous process (arrow, sp) and transverse processes (asterisks, tp) in the knockout mice.
Fig. 4
Fig. 4
Radiographs of the skull from superior (A) and lateral (B) aspect in normal (WT) and myostatin-deficient (KO) mice showing the flaring zygomatic arches (arrow, A) in the knockout mice and the more elongate skull (arrow, B) in the wild-type mice.

References

    1. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997 May 1;387(6628):83–90. - PubMed
    1. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004;20:61–86. - PubMed
    1. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004 Jun 24;350(26):2682–2688. - PubMed
    1. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002 Mar;109(5):595–601. - PMC - PubMed
    1. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Jun;4(2):157–166. - PubMed

Publication types

MeSH terms